KODIAK SCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.42 USD | +1.79% |
|
-11.63% | +12.50% |
| Apr. 04 | UBS Adjusts Kodiak Sciences Price Target to $5 From $3, Maintains Neutral Rating | MT |
| Apr. 01 | Barclays Raises Price Target on Kodiak Sciences to $3 From $2, Maintains Underweight Rating | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 179M |
|---|---|---|---|---|---|
| Net income 2024 * | -225M | Net income 2025 * | -267M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 58.45M | Net cash position 2025 * | 8.2M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.84
x | P/E ratio 2025 * |
-0.9
x | Employees | 111 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kodiak Sciences Inc.
More recommendations
More press releases
| 1 day | +1.79% | ||
| 1 week | -11.63% | ||
| Current month | -34.98% | ||
| 1 month | -45.28% | ||
| 3 months | +4.59% | ||
| 6 months | +101.18% | ||
| Current year | +12.50% |
1 week
3.29
3.93
1 month
3.297.77
Current year
2.877.77
1 year
1.379.80
3 years
1.37131.97
5 years
1.37171.21
10 years
1.37171.21
| Managers | Title | Age | Since |
|---|---|---|---|
Victor Perlroth
CEO | Chief Executive Officer | 51 | 08-12-31 |
John Borgeson
DFI | Director of Finance/CFO | 62 | 15-12-31 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 15-08-31 |
Tai Yin Yang
BRD | Director/Board Member | 70 | 19-12-16 |
Richard Levy
BRD | Director/Board Member | 66 | 18-07-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +4.69% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 3.42 | +1.79% | 314,299 |
| 24-04-19 | 3.36 | -3.17% | 604,281 |
| 24-04-18 | 3.47 | -3.61% | 566,652 |
| 24-04-17 | 3.6 | -7.46% | 607,767 |
| 24-04-16 | 3.89 | +0.52% | 372,226 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotes
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
3.42
USD
Average target price
4.25
USD
Spread / Average Target
+24.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.50% | 179M | |
| +2.49% | 96.73B | |
| -1.86% | 21.31B | |
| -16.61% | 21.21B | |
| -5.80% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- KOD Stock
